Jr., Ph.D., Group Director, Pharmacodiagnostics, Bristol-Myers Squib
Dr. Novotny is member of BMS’ Pharmacodiagnostics Center of Excellence, whose mission is to drive biomarker strategy, optimize biomarker knowledge and tools across all of R&D and execute on the integrated co-development and co-commercialization of diagnostic tests as companions to Bristol-Myers Squibb medicines. Dr. Novotny is responsible for the execution of BMS co-development collaborations for the company’s immuno-oncology pipeline. Dr. Novotny joined Bristol-Myers Squibb in 2011. Prior to his current role, he held positions at Roche Molecular Systems and worked as a consultant in the diagnostic industry. He received his Ph.D. from North Carolina State University.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Undeniably, cancer immunotherapy is one of the most promising areas in cancer research. New clinical trial approaches are under way to advance immune therapies for cancer. We will hear from both industry and medical representatives about their novel and innovative programs, which have the goal of expediting immunotherapy cancer treatments and delivering better patient outcomes.